Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32841231
Zhou Y, et al. (2020) Distinct and sequential re-replication barriers ensure precise genome duplication. PLoS Genet 16, e1008988 32841231
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T29-p - CDT1 (human)
Modsite: PPkLACRtPsPARPA SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): T29‑p, CDT1 (mouse): T28‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase

S31-p - CDT1 (human)
Modsite: kLACRtPsPARPALR SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): S31‑p, CDT1 (mouse): S30‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase

S372-p - CDT1 (human)
Modsite: ARARNLIsPRMEkAL SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): S372‑p, CDT1 (mouse): T384‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase

S394-p - CDT1 (human)
Modsite: AAPssPGsPrPALPA SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): S394‑p, CDT1 (mouse): T406‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase

T402-p - CDT1 (human)
Modsite: PrPALPAtPPAtPPA SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): T402‑p, CDT1 (mouse): T414‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MCM2 (human) Disrupts co-immunoprecipitation, pull-down assay
Comments:  inhibits Chk1 phosphorylation

T406-p - CDT1 (human)
Modsite: LPAtPPAtPPAAsPs SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): T406‑p, CDT1 (mouse): T418‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MCM2 (human) Disrupts pull-down assay, co-immunoprecipitation
Comments:  inhibits Chk1 phosphorylation

S411-p - CDT1 (human)
Modsite: PAtPPAAsPsALkGV SwissProt Entrez-Gene
Orthologous residues
CDT1 (human): S411‑p, CDT1 (mouse): S423‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
SB203580 nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII nocodazole no effect upon treatment-induced increase
JNK_inhibitor_VIII, SB203580 nocodazole no effect upon treatment-induced increase
RO-3306 nocodazole inhibit treatment-induced increase
CVT-313 nocodazole no effect upon treatment-induced increase
CVT-313, RO-3306 nocodazole inhibit treatment-induced increase
calyculin_A nocodazole, RO-3306 inhibit treatment-induced decrease
okadaic_acid nocodazole, RO-3306 no effect upon treatment-induced decrease
calyculin_A increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MCM2 (human) Disrupts pull-down assay, co-immunoprecipitation
Comments:  inhibits Chk1 phosphorylation